APO-GRANISETRON granisetron hydrochloride 1mg/1mL injection ampoule

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

granisetron hydrochloride, Quantity: 1.12 mg (Equivalent: granisetron, Qty 1 mg)

Disponible depuis:

Arrotex Pharmaceuticals Pty Ltd

DCI (Dénomination commune internationale):

granisetron hydrochloride

forme pharmaceutique:

Injection

Composition:

Excipient Ingredients: hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; citric acid monohydrate

Mode d'administration:

Intravenous

Unités en paquet:

5

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

Adults: Granisetron Injection is indicated for use in adults for:,The prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy;,The prevention of nausea and vomiting induced by radiotherapy.,Granisetron Injection is also indicated for use in the prevention and treatment of post-operative nausea and vomiting.,Children: Granisetron injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Descriptif du produit:

Visual Identification: Granisetron Hydrochloride Injection, 1mg/1ml is a clear and colorless solution, in a type 1 glass ampoule; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2014-12-17